Paul A Newhouse
Vanderbilt University Medical Center · Vanderbilt University · Vanderbilt University Dept. of Psychiatry
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
10
all conditions, ClinicalTrials.gov
NIH grants tied to them
11
NIH RePORTER
Trial papers
39
PubMed author-name match
Trials
Studies that name Paul A Newhouse as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:52 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06432166 · 2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's PatientsMTI Biotech Inc · not yet recruiting · Alzheimer Disease, Mild Cognitive Impairment · study chair
- Ph2NCT05231798 · Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and CognitionVanderbilt University Medical Center · recruiting · Down Syndrome, Down Syndrome, Partial Trisomy 21, Alzheimer Disease · principal investigator
- N/ANCT04230863 · Neuroplasticity-Based Cognitive Remediation for Chemotherapy-Related Cognitive ImpairmentVanderbilt University Medical Center · completed · Cancer Survivors, Chemotherapy-related Cognitive Impairment · principal investigator
- Early Ph1NCT04129060 · Cholinergic Health After Menopause (CHAMP)University of Vermont · completed · Postmenopausal Symptoms, Aging, Alzheimer Disease · principal investigator
- Ph1NCT04051801 · Multiple Ascending Dose Putative Cognitive Enhancer VU319Vanderbilt University Medical Center · withdrawn · Cognitive Impairment · principal investigator
- Ph1NCT03220295 · Putative Cognitive Enhancer VU319Vanderbilt University · completed · Cognitive Impairment · principal investigator
- Ph2NCT02312934 · Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot StudyVanderbilt University Medical Center · completed · Chemo Brain, Chemotherapy-related Cognitive Impairment, Chemo Fog · principal investigator
- Ph1/Ph2NCT01778946 · Nicotine Treatment of Cognitive Decline in Down SyndromeVanderbilt University Medical Center · completed · Down Syndrome, Mild Cognitive Impairment · principal investigator
- Ph2NCT01012375 · Study to Investigate the Efficacy and Tolerability of AZD1446 in Adult ADHD Patients.AstraZeneca · completed · Adult ADHD · principal investigator
- Ph2NCT00006399 · Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's DiseaseNational Center for Research Resources (NCRR) · completed · Alzheimer Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical CoreP20AG068082 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2020 to 2023 · $618,996 awarded in 2023Same name and institution; not confirmed by an ID
- Health of the Cholinergic System and Risk for Alzheimer's Disease in Postmenopausal WomenR01AG066159 · NIA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · fiscal years 2019 to 2023 · $1,690,482 awarded in 2023Same name and institution; not confirmed by an ID
- Long-Term Nicotine Treatment of Mild Cognitive ImpairmentR56AG047992 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2022 · $6,088,879 awarded in 2022Same name and institution; not confirmed by an ID
- The cholinergic integrity in Down syndrome in association with aging, Alzheimer's disease pathology, and cognitionR21AG075643 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2022 · $475,750 awarded in 2022Same name and institution; not confirmed by an ID
- Long-Term Nicotine Treatment of Mild Cognitive Impairment - Bridge FundingR01AG047992 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · fiscal years 2015 to 2021 · $2,000,351 awarded in 2021Same name and institution; not confirmed by an ID
- Multisensory Processing Across Lifespan and Links to CognitionR21CA183492 · NCI · VANDERBILT UNIVERSITY · fiscal years 2013 to 2014 · $196,250 awarded in 2014Same name and institution; not confirmed by an ID
- Estrogen Effects on Cholinergic Function in Older WomenR01AG021476 · NIA · VANDERBILT UNIVERSITY · fiscal years 2003 to 2013 · $510,426 awarded in 2013Same name and institution; not confirmed by an ID
- ESTRADIOL EFFECT ON BRAIN ACTIVIATION TO EMOTIONAL STIMULI IN OLDER WOMENM01RR000109 · NCRR · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · fiscal years 1990 to 2010 · $22,252 awarded in 2010Same name and institution; not confirmed by an ID
- Estrogen Effects on Cholinergic Function in Older WomenR56AG021476 · NIA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · fiscal years 2008 · $413,824 awarded in 2008Grant number is on one of their registry trials
- Transdermal Nicotine Treatment of MCIR01AG022462 · NIA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · fiscal years 2003 to 2007 · $150,000 awarded in 2007Same name and institution; not confirmed by an ID
- NICOTINIC CHOLINERGIC MODEL OF DEMENTIAR29MH046625 · NIMH · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · fiscal years 1990 to 1994 · $109,550 awarded in 1994Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:52 UTC. The ranking covers the 200 most relevant of 39 PubMed records, and a shared surname and initials can bring in a namesake. All 39 on PubMed
- Intravenous nicotine in Alzheimer's disease: a pilot study.Psychopharmacology (Berl) · 1988248 citationsRCR 9.2
- L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.Arch Gen Psychiatry · 1987176 citationsRCR 8.4
- Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder.Psychopharmacology (Berl) · 2004133 citationsRCR 3.9
- Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease.Psychopharmacology (Berl) · 1999131 citationsRCR 3.8
- Acute nicotinic blockade produces cognitive impairment in normal humans.Psychopharmacology (Berl) · 1992122 citationsRCR 4.2
- Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder.Pharmacol Biochem Behav · 2008122 citationsRCR 3.9
- Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior.Neuropsychopharmacology · 1994109 citationsRCR 3.7
- A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients.J Clin Psychiatry · 200097 citationsRCR 3.5
- High-dose selegiline in treatment-resistant older depressive patients.Arch Gen Psychiatry · 199496 citationsRCR 4.2
- Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study.J Clin Psychiatry · 199282 citationsRCR 3.6